bosutinib isomer (Fox Chase Cancer Center/Priaxon)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namebosutinib isomer (Fox Chase Cancer Center/Priaxon)
Drug Alias NameChk1/Wee1 inhibitors (Fox Chase Cancer Center/Priaxon)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitorsCheckpoint kinase 1 inhibitorsBcr-Abl tyrosine kinase inhibitors
TargetsSerine/threonine-protein kinase WEE1Checkpoint kinase 1Bcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFox Chase Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFox Chase Cancer CenterPriaxon Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A